Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Report Overview

The total market value for the 15MM, which includes both cell therapies and established/traditional CLL therapies was $13.2 billion in 2021. Allogeneic stem cell transplant is becoming less popular due to high levels of morbidity and CAR-T seems an attractive replacement to induce long-term disease control.

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Outlook, 2021-2031 ($ Billion)

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Outlook, 2021-2031 ($ Billion)

Buy the Full Report to Know More about Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Forecast

Download A Free Report Sample

The  CLL– cell therapies 15-market research report offers a comprehensive insight into the market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.

Market Size (2021) $13.2 billion
Forecast Period 2021-2031
Key Regions ·       APAC

·       Europe

·       Middle East

·       North America

Leading Players ·       Sian Wuhan Medical Technology Co Ltd

·       (Bristol Myers Squibb) Celgene Corp

·       Autolus Therapeutics

·       Gilead

·       Kite Pharma (Gilead)

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Dynamics

More targeted therapies entering earlier lines of therapy may reduce patient numbers entering the R/R setting where cell therapy is expected to launch or may provide direct competition to cell therapy. However, CAR-T usage in patients with del17p/TP53 mutations will be driven by the unmet need for more treatments that can induce long-term disease control. Moreover, CAR-T is also an attractive option for R/R patients who have progressed on targeted therapy. This, in turn, will propel the market growth during the forecast period.

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Analysis by Treatment

  • More targeted therapies such as next-generation BTK and BCL2 inhibitors will provide more treatment options. However, patients with del17p/TP53 mutations tend to cycle through the available options quickly and relapse sooner.
  • Young patients stand to benefit from time-limited therapy options as opposed to agents like Imbruvica that require daily treatment until progression. For instance, Venclexta plus Gazyva is designed to be completed within 12 months and induce long-term remission thereafter.

Buy Full Report for More Insights into the Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Treatment

Download a Free Report Sample

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Segmentation by Regions

North America had the highest sales in 15MM in the CLL-cell therapies 15-market.

A few of the key regions in the market are APAC, Europe, Middle East, and North America.

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Analysis by Regions, 2021 (%)

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Analysis by Regions, 2021 (%)

Buy the Full Report for More Regional Insights into the Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market

Download A Free Report Sample

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market -Competitive Landscape

Key future players in the cell therapy market in CLL consist mostly of small- to medium-sized biotech companies based in the US or China. This includes companies that are well-established in the CGT space outside of CLL, such as Juno Therapeutics approved in non-Hodgkin’s lymphoma [NHL]), and Kite Pharma among others.

A few of the major players in the chronic lymphocytic leukemia (CLL) – -cell therapies 15-market are:

  • Sian Wuhan Medical Technology Co Ltd
  • (Bristol Myers Squibb) Celgene Corp
  • Autolus Therapeutics
  • Gilead
  • Kite Pharma (Gilead)

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Analysis by Companies

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Analysis by Companies

Buy the Full Report to Know More about Companies in the Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market

Download A Free Report Sample

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Country Outlook (Value, $ Billion, 2021-2031)

  • APAC
  • Europe
  • Middle East
  • North America

Scope

  • The report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action, and cell & gene therapies by class, including early- to late clinical-stage pipeline products with launch date assessment by the 8 major markets.
  • The forecast includes 8 countries for the period of 2021-2031.
  • Seven markets are extrapolated obtaining a 15-market value for all CLL therapeutics.

Reasons to Buy

  • Get cell therapy sales forecasts across multiple regions
  • Gain insight into promising early-stage approaches

Our indication-specific forecast models answer questions such as:

  • What is the target patient pool for cell & gene therapies in each cancer indication?
  • Which patient groups are more likely to receive these therapies?
  • What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication
  • What is the anticipated breakdown between autologous and allogeneic cell therapies?
  • When will cell & gene therapies launch in each market?
  • What is the total market value projected for the forecast end, in 2031?

BMS
Autolus Therapeutics
Sian Wuhan Medical Technology

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1. Contents

1.2. Report Scope

2. Executive Summary

3. Disease Overview

4. Pipeline Drugs Overview

4.1. Pipeline Analysis

4.2. Target Analysis and Clinical Benchmarks

5. Market Outlook

5.1. 10-Year Market Analysis with Drivers and Barriers

5.2. 10-Year Market Analysis with Drivers and Barriers – 15 Markets

6. Unmet Needs

7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis

8. Competitive Assessment

8.1. Competitive Analysis by Class of Therapy

9. Future Players and Catalyst

9.1. Future Players Based on Pipeline Strength

10. Appendix

10.1. Cell Therapies Forecast Methodology Overview

10.2. Pricing of Cell Therapies

10.3. Pipeline Launch Assumptions

10.4. Abbreviations

10.5. Methodology

10.6. About the Authors

11. Contact Us

Frequently asked questions

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 standard reports
Currency USD
$9,995

Can be used by individual purchaser only

$29,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 in real time.

  • Access a live Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.